University Clinical Center of Serbia - Clinic of Alergology and Imunology
Welcome,         Profile    Billing    Logout  
 11 Trials 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wei, Wei
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting
4
466
RoW
Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638
The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.
Renal Insufficiency, Chronic
10/25
03/26
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Active, not recruiting
3
488
RoW
BAT5906 injection, Lucentis
Bio-Thera Solutions
Neovascular (Wet) Age-related Macular Degeneration
04/24
06/25
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
HAIC, NCT06041477: Concurrently vs Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable HCC

Recruiting
3
540
RoW
Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Hepatic arterial infusion chemotherapy (HAIC), Concurrent Lenvatinib, Concurrent targeted therapy, Concurrent PD-1 antibody, Concurrent immunotherapy, Sequential Lenvatinib, Sequential targeted therapy, Sequential PD-1 antibody, Sequential immunotherapy
Sun Yat-sen University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan
Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
07/27
07/30
IBS-D, NCT05687435: Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Not yet recruiting
2/3
240
NA
Changyanning tablet, Changyanning tablet placebo
Mei Han
Diarrhea-Predominant Irritable Bowel Syndrome
01/23
04/24
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT05212051: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Recruiting
2
120
RoW
JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Active Ankylosing Spondylitis
11/22
01/23
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Recruiting
2
120
RoW
JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Non-radiographic Axial Spondyloarthritis
04/23
06/23
NCT06301828: Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Recruiting
2
16
RoW
Envafolimab Injection, KN035, Endostar, Recombinant Human Endostatin Injection
Nanjing First Hospital, Nanjing Medical University
Gastrointestinal Neoplasms
06/25
02/26
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting
2
186
RoW
Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus, SLE
08/25
05/26
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Recruiting
2
180
RoW
TQH3821 tablets 200 mg, TQH3821 tablets matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis
06/24
12/24
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Recruiting
2
296
RoW
Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control
Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan
Connective Tissue Diseases, Thrombocytopenia
12/25
12/25
BAT5906-003-CR, NCT04772105: Clinical Study of the Safety and Efficacy of BAT5906 Injection

Completed
1/2
60
RoW
2.5mg of BAT5906, 4.0mg of BAT5906
Bio-Thera Solutions
Diabetic Macular Edema
11/23
11/23
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Completed
1
92
RoW
Telitacicept, RC18, standard therapy
RemeGen Co., Ltd.
Systemic Lupus Erythematosus
10/23
11/23
NCT04714918: Chinese CKD-MBD Prevalence Survey (CRISS-MBD)

Recruiting
N/A
10254
RoW
Limeng Chen
Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder
12/24
12/24
NCT06297889: Effect of Core Strength Training on the Physical Fitness and Skills of Youth Field Hockey Players in China

Recruiting
N/A
48
RoW
core strength training 1-6weeks, core strength training 7-12weeks
Universiti Putra Malaysia
Player
06/24
06/24
NCT06662071: A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology

Recruiting
N/A
293
RoW
Organoid culture
Qilu Hospital of Shandong University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Hospital, The Third Shandong Provincial Hospital, Taian City Central Hospital, Weifang People's Hospital, Binzhou Medical University, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Liaocheng People's Hospital, Linyi People's Hospital, Yantai Yuhuangding Hospital, Zibo Central Hospital, Dezhou People's Hospital, The Affiliated Hospital of Jining Medical University and Zaozhuang City, Qilu Hospital of Shandong University (Qingdao)
Bladder Cancer
09/28
09/28
NCT06011980: Life-2023-02 Esophagogastric Variceal Bleeding

Recruiting
N/A
33
RoW
Growth Inhibitor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Acute Esophageal Variceal Hemorrhage
05/26
08/26
IBS, NCT06013410: Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome

Recruiting
N/A
30
RoW
colonoscopy
Second Affiliated Hospital, School of Medicine, Zhejiang University, Jinhua Hospital
Irritable Bowel Syndrome
05/26
05/26
CAPSTONE, NCT05230017: Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks

Recruiting
N/A
2000
RoW
Peking Union Medical College Hospital
Anti Phospholipid Syndrome
12/26
12/26
He, Lan
NCT04966884: The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

Recruiting
4
20
RoW
JAK Inhibitor
First Affiliated Hospital Xi'an Jiaotong University
Dermatomyositis, Adult Type
12/21
12/21
NCT05129410: Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells

Recruiting
4
20
RoW
Mycophenolate Mofetil
First Affiliated Hospital Xi'an Jiaotong University
Idiopathic Inflammatory Myopathy, Interstitial Lung Disease
11/22
11/23
MRBS, NCT04893161: A Model About the Response of Belimumab in SLE

Not yet recruiting
4
72
NA
Belimumab, The standard care
First Affiliated Hospital Xi'an Jiaotong University
Systemic Lupus Erythematosus
01/26
01/26
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
07/27
07/27
NCT05407246: Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis

Completed
2
90
RoW
Hemay005, placebo
Tianjin Hemay Pharmaceutical Co., Ltd
Active Ankylosing Spondylitis
08/23
08/23
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting
2
186
RoW
Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus, SLE
08/25
05/26
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Completed
1
92
RoW
Telitacicept, RC18, standard therapy
RemeGen Co., Ltd.
Systemic Lupus Erythematosus
10/23
11/23
CORN, NCT05339425: Chinese Osteoporotic Fracture Registration Network Platform

Recruiting
N/A
50000
RoW
No additional intervention will be administered.
Peking Union Medical College Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Tianjin First Central Hospital, Hebei Medical University Third Hospital, Dalian Hospital of Chinese Traditional and Western Medicine, The Second Affiliated Hospital of Harbin Medical University, Peking University Third Hospital, Beijing Shijingshan Hospital, The Second Medical Center of The General Hospital of the People's Liberation Army, Huamei hospital, University of Chinese Academy of Sciences, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, Ruijin Hospital, The First People's Hospital of Changzhou, Affiliated Hospital of Nantong University, Nantong First People's Hospital, Shanghai Changzheng Hospital, Wuhan Union Hospital, China, Central South University, Guangdong Provincial People's Hospital, Nanfang Hospital of Southern Medical University, Lunjiao Hospital of Shunde Foshan, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou Second Hospital, Second Affiliated Hospital of Guangzhou Medical University, Shenzhen Second People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Sichuan Provincial People's Hospital, West China Fourth Hospital, Sichuan Province Orthopedic Hospital, The Second Affiliated Hospital of Chongqing Medical University, Daping Hospital, Army Medical Center of PLA, Guizhou Provincial Orthopedics Hospital, First Affiliated Hospital Xi'an Jiaotong University, Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, The First Affiliated Hospital of Zhengzhou University
Osteoporosis, Osteoporotic Fractures
12/24
12/24
Arandjelovic, Snezana
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25

Download Options